TGFB1 and cancer: The mesenchymal cancer clones were found to have increased intrinsic TGF-β pathway activity and increased capacity to resist attacks by immune cytotoxic effector cells compared to the more epithelial clones, as reflected by reduced cancer cell susceptibility to CTL and NK cell-mediated lysis.